We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s New ‘Real-Time’ Review Aims to Speed New Cancer Drugs to Market
FDA’s New ‘Real-Time’ Review Aims to Speed New Cancer Drugs to Market
Sponsors of cancer drugs can apply for real-time review of their trial data if their investigational products demonstrate substantial improvements over available therapy and use straightforward study designs and endpoints that can be easily interpreted, according to a new FDA draft guidance.